StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Biogen cash

Cash and short-term investments held at the end of each period.

Biogen's cash was $1.30B at Sep 30, 2026. For fiscal 2025 it was $3.82B, up 60.7% from the year before. Over ten years it grew 11.3% a year on average. The highest annual figure on record is $4.89B in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.82B+60.7%
FY2024Dec 31, 2024$2.38B+126.2%
FY2023Dec 31, 2023$1.05B-78.5%
FY2022Dec 31, 2022$4.89B+28.7%
FY2021Dec 31, 2021$3.80B+45.7%
FY2020Dec 31, 2020$2.61B-41.7%
FY2019Dec 31, 2019$4.48B+26.5%
FY2018Dec 31, 2018$3.54B-4.1%
FY2017Dec 31, 2017$3.69B+58.6%
FY2016Dec 31, 2016$2.33B+77.9%
FY2015Dec 31, 2015$1.31B+8.6%
FY2014Dec 31, 2014$1.20B+100.0%
FY2013Dec 31, 2013$602.60M-64.7%
FY2012Dec 31, 2012$1.71B+0.9%
FY2011Dec 31, 2011$1.69B+40.0%
FY2010Dec 31, 2010$1.21B-4.4%
FY2009Dec 31, 2009$1.26B-5.8%
FY2008Dec 31, 2008$1.34B+103.4%
FY2007Dec 31, 2007$659.66M-0.3%
FY2006Dec 31, 2006$661.38M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.30B-67.1%
Q2 FY2026Jun 30, 2026$1.29B-53.4%
Q1 FY2026Mar 31, 2026$4.28B+64.8%
Q4 FY2025Dec 31, 2025$3.82B+60.7%
Q3 FY2025Sep 30, 2025$3.96B+133.1%
Q2 FY2025Jun 30, 2025$2.76B+44.5%
Q1 FY2025Mar 31, 2025$2.60B+141.8%
Q4 FY2024Dec 31, 2024$2.38B+126.2%
Q3 FY2024Sep 30, 2024$1.70B-25.7%
Q2 FY2024Jun 30, 2024$1.91B-68.6%
Q1 FY2024Mar 31, 2024$1.07B-78.7%
Q4 FY2023Dec 31, 2023$1.05B-78.5%
Q3 FY2023Sep 30, 2023$2.29B-53.4%
Q2 FY2023Jun 30, 2023$6.08B+26.7%
Q1 FY2023Mar 31, 2023$5.04B+34.4%
Q4 FY2022Dec 31, 2022$4.89B+28.7%
Q3 FY2022Sep 30, 2022$4.91B+66.2%
Q2 FY2022Jun 30, 2022$4.80B+57.3%
Q1 FY2022Mar 31, 2022$3.75B+47.9%
Q4 FY2021Dec 31, 2021$3.80B+45.7%
Q3 FY2021Sep 30, 2021$2.96B-17.5%
Q2 FY2021Jun 30, 2021$3.05B-29.5%
Q1 FY2021Mar 31, 2021$2.54B-34.3%
Q4 FY2020Dec 31, 2020$2.61B-41.7%
Q3 FY2020Sep 30, 2020$3.58B-19.3%
Q2 FY2020Jun 30, 2020$4.33B+46.6%
Q1 FY2020Mar 31, 2020$3.86B-1.2%
Q4 FY2019Dec 31, 2019$4.48B+26.5%
Q3 FY2019Sep 30, 2019$4.44B+0.2%
Q2 FY2019Jun 30, 2019$2.95B-8.4%
Q1 FY2019Mar 31, 2019$3.91B-4.8%
Q4 FY2018Dec 31, 2018$3.54B-4.1%
Q3 FY2018Sep 30, 2018$4.43B+186.1%
Q2 FY2018Jun 30, 2018$3.22B+175.7%
Q1 FY2018Mar 31, 2018$4.11B+344.6%
Q4 FY2017Dec 31, 2017$3.69B+58.6%
Q3 FY2017Sep 30, 2017$1.55B–
Q2 FY2017Jun 30, 2017$1.17B–
Q1 FY2017Mar 31, 2017$924.00M–
Q4 FY2016Dec 31, 2016$2.33B–

More Biogen figures

See a number that looks wrong?